Economic Considerations of the Treatment of Ankylosing Spondylitis
Authors:
- John D ReveilleJRJohn D Reveille
- Antonio XimenesAXAntonio Ximenes
- Michael M WardMWMichael M Ward
- 1 May 2012
- journal article
- review article
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 343 (5) , 371-374
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the diseaseClinical Rheumatology, 2011
- Cost of Illness from the Public Payers’ Perspective in Patients with Ankylosing Spondylitis in Rheumatological CareThe Journal of Rheumatology, 2010
- Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in GermanyRheumatology, 2010
- Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal costAnnals of the Rheumatic Diseases, 2010
- Costs and quality of life of patients with ankylosing spondylitis in Hong KongRheumatology, 2008
- The cost‐effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice dataScandinavian Journal of Rheumatology, 2008
- Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patientsClinical Rheumatology, 2007
- Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effectiveRheumatology, 2006
- Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countriesAnnals of the Rheumatic Diseases, 2003